ICAP

Eswatini

(Swaziland)

Where We Work Eswatini

Eswatini (Swaziland)

In the last decade, Eswatini has cut its rate of new HIV infections in half, according to the SHIMS (Swaziland HIV Incidence Measurement Survey) and SHIMS2 national population-based HIV impact assessment surveys conducted by the Ministry of Health and ICAP. The SHIMS 3 survey will soon determine further progress towards global HIV targets.

ICAP’s work in Eswatini is longstanding as a key technical and implementation partner for projects focusing on the prevention of maternal-to-child transmission (PMTCT), early infant diagnosis, HIV drug resistance surveillance, laboratory improvement, and ongoing training of health care workers, epidemiologists, and researchers.

ICAP in Eswatini also works in collaboration with the Eswatini Ministry of Health and Family Life Association of Eswatini to conduct clinical trials with investigational drugs and registered products through the Eswatini Prevention Center Clinical Research Site as part of ICAP’s Clinical Trials Unit. The clinical research is implemented in close collaboration with local stakeholders to strengthen clinical research systems and conduct studies that impact local and global public health programs. Over 2,400 participants from diverse populations have been enrolled in CRS studies and participated in studies relating to HIV prevention with oral and injectable pre-exposure prophylaxis (PrEP), COVID-19 vaccination, and HPV vaccination.

Download Country Brief
A person in protective clothing, mask, and gloves works in a lab, using a tool to handle petri dishes next to a flame.

Projects

CoVPN 3008: UBUNTU Study

  • current
The UBUNTU study is a research study evaluating the Moderna COVID-19 mRNA vaccine. We already know that this vaccine prevents COVID-19 disease, including severe COVID-19. The United States and many other countries use the Moderna vaccine. We want to know how many doses of vaccine are needed for protection against COVID-19 for adults living with ...
Learn More

HPTN 084 OLE Study

  • current
A Phase 3 Double-Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women Link: https://www.hptn.org/research/studies/hptn084 ...
Learn More

HPTN 084 Open Access

  • current
The purpose of this study is to evaluate eligible participants who have completed DAIDS-sponsored pre-exposure prophylaxis (PrEP) studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnoses, SAEs, Grade 3 and Grade 4 ISRs, and AEs leading to withdrawal. ...
Learn More

HPTN 104

  • current
A multisite, open-label, randomized crossover study comparing adherence to a single daily dual prevention pill (DPP) versus FTC/TDF and Combined Oral Contraception separate pill dosing (2PR), given for pre-exposure prophylaxis and pregnancy prevention in people of childbearing potential. The purpose of the study is to evaluate adherence to a single, dual prevention pill (DPP; co-formulated ...
Learn More

HPV Vaccine Study

  • current
A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults Living with HIV in Eswatini ...
Learn More

Population-based HIV Impact Assessment (PHIA)

  • Multi-Country,
  • current:
  • Cameroon
    • ,
  • Cote d’ Ivoire
    • ,
  • Democratic Republic of the Congo
    • ,
  • Eswatini
    • ,
  • Lesotho
    • ,
  • Malawi
    • ,
  • Tanzania
    • ,
  • Uganda
PHIA is a multi-country initiative led by ICAP, the U.S. Centers for Disease Control and Prevention (CDC), and ministries of health in PEPFAR-supported countries. Each survey offers household-based HIV counseling and testing conducted by trained survey staff, with return of results. The surveys also ask questions about access to preventive care and treatment services for adults and children. The results measure national and regional progress toward UNAIDS’ 90-90-90 goals and guide policy ...
Learn More

Reaching Impact, Saturation and Epidemic Control (RISE)

  • Multi-Country,
  • current
...
Learn More

Strengthening Surveillance Systems for Antimicrobial Resistance (Fleming Fund Country Grant Phase II)

  • current
ICAP is working with its partners to strengthen surveillance systems for antimicrobial resistance (AMR), antimicrobial use (AMU), and antimicrobial consumption (AMC) in both the human and animal sectors in Eswatini. This will include overseeing and monitoring surveillance systems and improving the capacity for AMR, AMC/AMU surveillance in the human and animal health sectors. ICAP will ...
Learn More

Strengthening the Delivery of Quality HIV/TB Laboratory Services in Eswatini (Eswatini Lab II)

  • current
ICAP is providing technical assistance to enhance laboratory systems through the implementation of laboratory quality management systems and accreditation; external quality assessment through proficiency testing of all laboratory testing areas; capacity building of the laboratory workforce; improved access to testing through decentralized laboratory services; and enhanced national sample transport systems. ICAP is also strengthening laboratory ...
Learn More

The CQUIN Project for Differentiated Service Delivery

  • Multi-Country,
  • current
CQUIN is a multi-country learning network dedicated to improving differentiated service delivery (DSD) for people living with HIV. Launched in 2017 with support from the Bill & Melinda Gates Foundation, the network convenes health system leaders from countries in sub-Saharan Africa to participate in joint learning and information exchange, with the goal of fostering scale-up ...
Learn More

ICAP in Eswatini

Active Years
  • 2005 till present
Key Technical Areas
  • HIV
  • Tuberculosis
  • COVID-19
  • Antimicrobial Resistance
  • Non-communicable Diseases
  • Human Resources for Health
  • Laboratory Systems Strengthening
  • Health Systems Strengthening
  • Monitoring and Evaluation
  • One Health
  • Maternal and Child Health
  • Research
  • Surveillance
  • Training and Education
  • Technical Assistance
Current Funders
  • Bill & Melinda Gates Foundation
  • U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) / U.S. Centers for Disease Control and Prevention (CDC)
  • Family Health International 360 National Institutes of Health
  • Fleming Fund

Country Director

Ruben Sahabo, MD

Dr. Ruben Sahabo is the country director for ICAP in Eswatini. Previously, he was the ICAP country director in Rwanda, where he led the rapid expansion of care and treatment activities, overseeing technical and financial assistance to over 50 urban and rural clinics that enrolled over 50,000 patients in HIV care and treatment. He also supported the start-up of ICAP’s programs in Côte d’Ivoire in 2008 and the Democratic Republic of Congo in 2010. Dr. Sahabo has managed numerous program evaluations and research studies in Rwanda and Eswatini and was co-investigator of an evaluation of the Diagnostic Chip for Infectious Diseases in Rwanda, an innovative strategy for an integrated point-of-care microfluidic-based diagnostic device based on “lab on a chip” technologies developed by Columbia University Microscale Bioengineering Laboratory.

Resources

Jobs in Eswatini

There are currently no job listings for this country. See the ICAP careers page to search all job listings.

News & Stories of Interest